S&P 500   4,284.52 (-0.08%)
DOW   33,390.48 (-0.35%)
QQQ   359.98 (+0.48%)
AAPL   172.87 (+0.97%)
MSFT   317.32 (+0.50%)
META   304.51 (+1.43%)
GOOGL   133.24 (+1.82%)
AMZN   129.10 (+1.56%)
TSLA   250.44 (+0.09%)
NVDA   448.50 (+3.11%)
NIO   8.77 (-2.99%)
BABA   86.20 (-0.62%)
AMD   102.20 (-0.60%)
T   14.82 (-1.33%)
F   12.27 (-1.21%)
MU   67.52 (-0.75%)
CGC   0.78 (-0.37%)
GE   109.28 (-1.15%)
DIS   80.89 (-0.20%)
AMC   7.86 (-1.63%)
PFE   33.33 (+0.48%)
PYPL   58.66 (+0.34%)
NFLX   380.30 (+0.72%)
S&P 500   4,284.52 (-0.08%)
DOW   33,390.48 (-0.35%)
QQQ   359.98 (+0.48%)
AAPL   172.87 (+0.97%)
MSFT   317.32 (+0.50%)
META   304.51 (+1.43%)
GOOGL   133.24 (+1.82%)
AMZN   129.10 (+1.56%)
TSLA   250.44 (+0.09%)
NVDA   448.50 (+3.11%)
NIO   8.77 (-2.99%)
BABA   86.20 (-0.62%)
AMD   102.20 (-0.60%)
T   14.82 (-1.33%)
F   12.27 (-1.21%)
MU   67.52 (-0.75%)
CGC   0.78 (-0.37%)
GE   109.28 (-1.15%)
DIS   80.89 (-0.20%)
AMC   7.86 (-1.63%)
PFE   33.33 (+0.48%)
PYPL   58.66 (+0.34%)
NFLX   380.30 (+0.72%)
S&P 500   4,284.52 (-0.08%)
DOW   33,390.48 (-0.35%)
QQQ   359.98 (+0.48%)
AAPL   172.87 (+0.97%)
MSFT   317.32 (+0.50%)
META   304.51 (+1.43%)
GOOGL   133.24 (+1.82%)
AMZN   129.10 (+1.56%)
TSLA   250.44 (+0.09%)
NVDA   448.50 (+3.11%)
NIO   8.77 (-2.99%)
BABA   86.20 (-0.62%)
AMD   102.20 (-0.60%)
T   14.82 (-1.33%)
F   12.27 (-1.21%)
MU   67.52 (-0.75%)
CGC   0.78 (-0.37%)
GE   109.28 (-1.15%)
DIS   80.89 (-0.20%)
AMC   7.86 (-1.63%)
PFE   33.33 (+0.48%)
PYPL   58.66 (+0.34%)
NFLX   380.30 (+0.72%)
S&P 500   4,284.52 (-0.08%)
DOW   33,390.48 (-0.35%)
QQQ   359.98 (+0.48%)
AAPL   172.87 (+0.97%)
MSFT   317.32 (+0.50%)
META   304.51 (+1.43%)
GOOGL   133.24 (+1.82%)
AMZN   129.10 (+1.56%)
TSLA   250.44 (+0.09%)
NVDA   448.50 (+3.11%)
NIO   8.77 (-2.99%)
BABA   86.20 (-0.62%)
AMD   102.20 (-0.60%)
T   14.82 (-1.33%)
F   12.27 (-1.21%)
MU   67.52 (-0.75%)
CGC   0.78 (-0.37%)
GE   109.28 (-1.15%)
DIS   80.89 (-0.20%)
AMC   7.86 (-1.63%)
PFE   33.33 (+0.48%)
PYPL   58.66 (+0.34%)
NFLX   380.30 (+0.72%)
NASDAQ:CGIX

Cancer Genetics (CGIX) Stock Forecast, Price & News

$0.17
0.00 (0.00%)
(As of 09/29/2023 ET)
Today's Range
$0.17
▼
$0.18
50-Day Range
N/A
52-Week Range
$2.11
▼
$17.50
Volume
47,144 shs
Average Volume
2.44 million shs
Market Capitalization
$694,450.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlinesSocial Media

CGIX stock logo

About Cancer Genetics (NASDAQ:CGIX) Stock

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.

CGIX Price History

CGIX Stock News Headlines

October 2, 2023 | americanbankingnews.com
Contrasting Cancer Genetics (CGIX) & Its Peers
October 2, 2023 | americanbankingnews.com
Head-To-Head Review: Cancer Genetics (CGIX) vs. Its Rivals
October 2, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
October 2, 2023 | americanbankingnews.com
Critical Analysis: Cancer Genetics (CGIX) and Its Competitors
September 28, 2023 | americanbankingnews.com
Analyzing Cancer Genetics (CGIX) and Its Rivals
September 27, 2023 | americanbankingnews.com
Head-To-Head Analysis: Cancer Genetics (CGIX) & Its Peers
September 26, 2023 | americanbankingnews.com
Cancer Genetics (NASDAQ:CGIX) Now Covered by StockNews.com
September 25, 2023 | americanbankingnews.com
Head-To-Head Comparison: Cancer Genetics (CGIX) and Its Rivals
October 2, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
September 25, 2023 | americanbankingnews.com
Financial Survey: Cancer Genetics (CGIX) versus Its Competitors
September 22, 2023 | americanbankingnews.com
Analyzing Cancer Genetics (CGIX) and Its Competitors
See More Headlines
Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medical Laboratories
Sub-Industry
N/A
Sector
Health Care and Social Assistance
Current Symbol
NASDAQ:CGIX
CUSIP
N/A
CIK
N/A
Web
www.cancergenetics.com
Phone
(201) 479-1357
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$6.33 million
Price / Sales
2.98
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,085,000
Free Float
N/A
Market Cap
$18.83 million
Optionable
Not Optionable
Beta
2.72
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Andrew D. C. LaFrence
    President, Chief Executive & Financial Officer













CGIX Stock - Frequently Asked Questions

How have CGIX shares performed in 2023?

Cancer Genetics' stock was trading at $0.1570 at the start of the year. Since then, CGIX shares have increased by 2,836.3% and is now trading at $4.61.
View the best growth stocks for 2023 here.

What is Panna Sharma's approval rating as Cancer Genetics' CEO?

28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cancer Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Activision Blizzard (ATVI), Ford Motor (F), Gilead Sciences (GILD), CymaBay Therapeutics (CBAY), Synergy Pharmaceuticals (SGYP) and TherapeuticsMD (TXMD).

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How do I buy shares of Cancer Genetics?

Shares of CGIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $4.61.

How much money does Cancer Genetics make?

Cancer Genetics (NASDAQ:CGIX) has a market capitalization of $18.83 million and generates $6.33 million in revenue each year.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 State Rt 17 Fl 2, Rutherford, New Jersey 07070-2597. The official website for the company is www.cancergenetics.com. The company can be reached via phone at (201) 479-1357.

This page (NASDAQ:CGIX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -